Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people notice Wegovy beginning to reduce their appetite within the first week or two of starting, though meaningful weight loss typically becomes visible over several weeks rather than days. The STEP 1 trial, published in the New England Journal of Medicine, found participants on semaglutide 2.4mg lost an average of around 15% of body weight over 68 weeks — a result built up gradually, not overnight. Wegovy (semaglutide) is a prescription-only medicine, and a clinician assesses whether it is suitable for you before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The first thing most people on Wegovy report is a quietening of hunger signals, often within three to five days of the initial injection. Semaglutide acts on GLP-1 receptors in the brain and gut, slowing gastric emptying and reducing the drive to eat. That effect starts from dose one. What it does not do, at least not immediately, is move the number on the scales by any meaningful amount. In those opening days the body is simply adjusting to the medicine's presence.
Nausea is common early on and tends to peak in the first week or so after each new dose, then ease. This is partly why the licensed schedule begins at 0.25mg, a level chosen for tolerability, giving your system time to settle before the dose climbs. You can read more about preparing for that adjustment period in our guide on how to prepare for Wegovy.
The practical upshot: if you inject on a Monday and feel no different by Thursday, that is normal. The question of how many days Wegovy takes to work depends partly on which effect you mean, appetite, weight, or both.
By weeks four to eight, most people who tolerate Wegovy well have moved up at least one dose tier and are starting to see measurable weight change. The NHS medicines page for semaglutide notes that treatment is assessed at six months, if less than 5% of starting weight has been lost by that point on the maintenance dose, continuing is reviewed. That six-month checkpoint is built into the clinical pathway precisely because results accumulate across months, not days.
Early weight loss in the first four weeks tends to be modest, often two to four pounds on average in trials. It accelerates as the dose increases and appetite suppression becomes more pronounced. If you have ever wondered whether your injection day matters, our page on what time of day is best for Wegovy covers the practicalities without overcomplicating them.
One thing worth noting: people who start treatment mid-week, or just before a bank holiday, sometimes feel the first week drags longer than it does. In reality the biology does not care whether it is payday or a Monday morning, the timeline is governed by pharmacology, not the calendar.
The STEP 1 trial data is clear that the steepest part of the weight-loss curve runs from roughly week 12 through to week 44 or so, before beginning to plateau. Average loss at 68 weeks was around 15% of body weight on the 2.4mg maintenance dose. More recently, the MHRA approved a higher 7.2mg dose, with trial data showing approximately 20.7% average loss over 72 weeks at that level, narrowing the gap with tirzepatide results considerably. Details on how Wegovy's evidence compares with other options are on our Wegovy vs Ozempic page and in the direct semaglutide comparison.
The practical message is that Wegovy is not a medicine whose results arrive in days. The first days bring appetite change; the first months bring measurable weight change; the full effect takes the better part of a year. That is consistent with how NICE frames it in its recommendation for semaglutide (TA875), which sets a six-month review point rather than a six-week one.
A few things can blunt or delay the expected response. Dose increases that happen more slowly than the four-weekly schedule (sometimes because side effects need more time to settle) push the timeline out. Illness or a period of higher stress may temporarily stall progress. And a small proportion of people on semaglutide find their response plateaus earlier than average, which is one reason tirzepatide (a dual GIP and GLP-1 receptor agonist) is sometimes considered instead. Our overview of Wegovy covers the full licensed picture, and if you are thinking about cost as part of your decision, the Wegovy price guide explains what a legitimate private prescription typically includes.
People transferring from another injectable, such as liraglutide, sometimes find the adjustment to semaglutide's rhythm feels different, if that applies to you, the guide on switching from Saxenda to Wegovy walks through what to expect. The broader question of how weeks, not just days, shape the outcome is covered in our piece on how many weeks Wegovy takes to work.
None of this replaces the conversation with a prescriber, who can assess your individual picture. If Wegovy looks right for your situation, check your eligibility with our clinical team, consultations are free, reviewed the same day by a GPhC-registered prescriber, and there are no subscriptions or hidden fees.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.